

GLAXOSMITHKLINE PLC
Form 6-K
November 12, 2008

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending November 11, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

.

Date:

11 November 2008

Name of
applicant

GlaxoSmithKline plc

:

Name of scheme:

GlaxoSmithKline Share Option
Plan - Ordinary Shares

Period of return: From: 1 May 2008 To: 31 October 2008

Balance of unallotted

securities under
scheme(s) from
previous return:

6,346,495

Plus:

The amount by which
the block scheme(s)
has been increased
since the date of the
last return (if any
increase has been
applied for):

0

Less:

Number of
securities

348,670

issued/allotted under
scheme(s) during period
(see LR3.5.7G):

Equals:

5,997,825

Balance under

scheme(s) not yet

issued/allotted at end of

period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an *ris*.

Date:

11 November 2008

Name of <i>applicant</i>	GlaxoSmithKline plc
:	
Name of scheme:	GlaxoSmithKline Share Option Plan - ADS
Period of return:	From: 1 May 2008 To: 31 October 2008
Balance of unallotted securities under scheme(s) from previous return:	8,406,586
<i>Plus:</i>	
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0
<i>Less:</i>	2,008,762
Number of	

securities

issued/allotted under
scheme(s) during period
(see LR3.5.7G):

Equals:

Balance under
scheme(s) not yet 6,397,824
issued/allotted at end of
period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this
form
must be typed or printed electronically
and
provided to an
ris

Date:

11 November 2008

Name of
applicant GlaxoSmithKline plc
:
Name of scheme: Glaxo Wellcome
 UK
 Share Option Scheme
Period of return: From: 1 May 2008 To: 31 October 2008
Balance of unallotted
securities under
scheme(s) from 5,119,750
previous return:

Plus:

The amount by which
the block scheme(s)
has been increased 0
since the date of the
last return (if any
increase has been
applied for):

Less:

Number of
securities 0
issued/allotted under
scheme(s) during period
(see LR3.5.7G):

Equals:

Balance under
scheme(s) not yet 5,119,750
issued/allotted at end of
period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this
form
must be typed or printed electronically
and
provided to an
ris
.

Date:

11 November 2008

Name of GlaxoSmithKline plc

applicant

:

Name of scheme: Glaxo Wellcome International
Share Option Scheme

Period of return: From: 1 May 2008 To: 31 October 2008

Balance of unallotted
securities under
scheme(s) from
previous return: 13,267,156

Plus:

The amount by which
the block scheme(s)
has been increased
since the date of the
last return (if any
increase has been
applied for): 0

Less:

Number of
securities
issued/allotted under 0
scheme(s) during period
(see LR3.5.7G):

Equals:

Balance under
scheme(s) not yet 13,267,156
issued/allotted at end of
period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this
form
must be typed or printed electronically
and

provided to an
ris

Date:

11 November 2008

Name of <i>applicant</i>	GlaxoSmithKline plc
:	
Name of scheme:	Glaxo Wellcome 1999 Share Option Plan
Period of return: From:	1 May 2008 To: 31 October 2008
Balance of unallotted securities under scheme(s) from previous return:	1,040,000
<i>Plus:</i>	
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0
<i>Less:</i>	
Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):	0
<i>Equals:</i>	
Balance under scheme(s) not yet issued/allotted at end of period:	1,040,000

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an *ris*.

Date:

11 November 2008

Name of <i>applicant</i>	GlaxoSmithKline plc
:	
Name of scheme:	SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares
Period of return:	From: 1 May 2008 To: 31 October 2008
Balance of unallotted securities under scheme(s) from previous return:	163,606
<i>Plus:</i>	
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0
<i>Less:</i>	
Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):	0
<i>Equals:</i>	
Balance under scheme(s) not yet issued/allotted at end of period:	163,606

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an *ris*.

Date:

11 November 2008

Name of *applicant*: GlaxoSmithKline plc
Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS
Period of return: From: 1 May 2008 To: 31 October 2008
Balance of unallotted securities under scheme(s) from previous return: 275,420
Plus:
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less: 0
Number of *securities* issued/allotted under scheme(s) during period

(see LR3.5.7G):

Equals:

Balance under
scheme(s) not yet 275,420
issued/allotted at end of
period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this
form
must be typed or printed electronically
and
provided to an
ris

Date:

11 November 2008

Name of
applicant GlaxoSmithKline plc
:
Name of scheme: SmithKline Beecham 1989
Executive Share Option Plan -
Unapproved - Ordinary
Period of return: From: 1 May 2008 To: 31 October 2008
Balance of unallotted
securities under
scheme(s) from 100,000
previous return:
Plus: 0
The amount by which
the block scheme(s)

has been increased since the date of the last return (if any increase has been applied for):

Less:

Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals:

Balance under scheme(s) not yet issued/allotted at end of period: 100,000

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an *ris*.

Date:

11 November 2008

Name of applicant: GlaxoSmithKline plc
Name of scheme:

GlaxoSmithKline Savings Related
Share Option Scheme

Period of return: From: 1 May 2008 To: 31 October 2008

Balance of unallotted
securities under
scheme(s) from
previous return: 6,317,082

Plus:

The amount by which
the block scheme(s)
has been increased
since the date of the
last return (if any
increase has been
applied for): 0

Less:

Number of
securities
issued/allotted under
scheme(s) during period
(see LR3.5.7G): 129,432

Equals:

Balance under
scheme(s) not yet
issued/allotted at end of
period: 6,187,650

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: November 11, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc